Prevail Therapeutics Inc. Common Stock
PRVL
PRVL was delisted on the 21st of January, 2021.
38 hedge funds and large institutions have $349M invested in Prevail Therapeutics Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
77.71% more ownership
Funds ownership: 0% → 77.71% (+78%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$201M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$40M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$34.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.3M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$16.4M |
Top Sellers
PRVL Hedge Fund Activity: Q2 2019 in Review
38 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q2 2019, worth a combined $349M.
Buyers outnumbered sellers: 38 funds opened new PRVL positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $201M.
- 38 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $349M of Prevail Therapeutics Inc. Common Stock stock for Q2 2019.
- 38 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +38 holders.
- The largest Prevail Therapeutics Inc. Common Stock buyer in Q2 2019 was OrbiMed, an estimated $201M added.
Based on aggregated 13F filings for Q2 2019.